Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | PRF1 | P14222 | 5/20 | 0.59 |
| ▸ | MAOA | P21397 | 5/20 | 0.55 |
| ▸ | MAOB | P27338 | 5/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30372059 | 1.00 | MAPT (0.61) | MAPTLMNAGAAPRF1MAOA | |
| SCHEMBL26767262 | 0.91 | MAPT (0.51) | MAPTLMNAGAAPRF1MAOA | |
| SCHEMBL29853499 | 0.91 | MAPT (0.51) | MAPTLMNAGAAPRF1MAOA | |
| SCHEMBL26774070 | 0.89 | ALDH1A1 (0.54) | MAPTLMNAGAAPRF1MAOA | |
| SCHEMBL26767242 | 0.85 | ALDH1A1 (0.48) | MAPTLMNAGAAPRF1MAOA | |
| SCHEMBL6585556 | 0.84 | MAPT (0.60) | MAPTLMNAGAAPRF1MAOA | |
| SCHEMBL30080977 | 0.84 | MAPT (0.60) | MAPTLMNAGAAPRF1MAOA | |
| SCHEMBL26773974 | 0.82 | PRF1 (0.45) | MAPTLMNAGAAPRF1MAOA | |
| SCHEMBL26767254 | 0.81 | PRF1 (0.44) | MAPTLMNAGAAPRF1MAOA | |
| SCHEMBL26773975 | 0.81 | PRF1 (0.44) | MAPTLMNAGAAPRF1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| CN-119371391-A | Aroyl compound and preparation method and application thereof | 河北医科大学 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024086644-A1 | CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024015412-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3820573-B1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023061999-A1 | PROCESS FOR PREPARING A PHENOLIC HYDROCARBON | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-04-20 | — | — | WO | disclosed |
| EP-1490356-A1 | (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003084951-A1 | (3Z) -3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| EP-1159274-B1 | METHOD FOR THE PREPARATION OF CITALOPRAM | LUNDBECK & CO AS H (DK) | 2003-03-26 | — | — | EP | disclosed |
| US-20020077353-A1 | Method for the preparation of citalopram | H. LUNDBECK A/S (DK) | 2002-06-20 | — | — | US | disclosed |
| EP-1159274-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. Lundbeck A/S (DK) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000013648-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-03-16 | — | — | WO | disclosed |
| EP-0145078-B1 | DIPHENYL ETHER HERBICIDES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-10-12 | — | — | EP | disclosed |
| EP-0145078-A2 | Diphenyl ether herbicides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1985-06-19 | — | — | EP | disclosed |
| US-4279823-A | REACTION WITH A THALLIUM SALT THAN WITH A CARBON MONOXIDE IN THE PRESENCE OF A NOBLE METAL CATALYST | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1981-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | MAPT 3114/4885LMNA 952/4885GAA 4432/4885 |
| US-20020077353-A1 | Method for the preparation of citalopram | MAOB, MAOA, CYP4F3 | MAPT 1841/4885LMNA 2665/4885GAA 981/4885 |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | MAPT 2710/4885LMNA 3822/4885GAA 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.